Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA7 | P43166 | 4/20 | 0.44 |
| ▸ | CA9 | Q16790 | 4/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1894879 | 0.84 | LMNA (0.52) | LMNASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL7698241 | 0.83 | LMNA (0.61) | LMNASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL286585 | 0.81 | LMNA (0.50) | LMNASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL26104183 | 0.81 | RAB9A (0.54) | LMNASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL20177039 | 0.81 | LMNA (0.53) | LMNASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL20269905 | 0.81 | LMNA (0.50) | LMNASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL973113 | 0.81 | LMNA (0.50) | LMNASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL8072052 | 0.81 | LMNA (0.56) | LMNASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL286134 | 0.80 | CA12 (0.43) | LMNASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL17662696 | 0.80 | KDM4E (0.37) | LMNASMN1; SMN2NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822953-B9 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2822953-B1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2758402-B9 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2758402-B9 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2758402-B1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2758402-B1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER (US) | 2016-04-27 | — | — | EP | disclosed |
| US-9133215-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133215-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150203502-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER (US) | 2015-07-23 | — | — | US | disclosed |
| US-20150203502-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER (US) | 2015-07-23 | — | — | US | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| EP-2097419-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | Exelixis, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090042726-A1 | Novel Herbicides | SYNGENTA LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042726-A1 | Novel Herbicides | SYNGENTA LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042726-A1 | Novel Herbicides | SYNGENTA LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| EP-1965644-A1 | NOVEL HERBICIDES | Syngenta Limited (GB) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071900-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071900-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247559-A1 | Benzofuropyrimidinones | F12, BRI3BP, BRD1 | LMNA 2545/4885SMN1; SMN2 1926/4885NPC1 2168/4885 |
| US-20150203502-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | TYMP, DPYD, TYMS | LMNA 3892/4885SMN1; SMN2 2215/4885NPC1 4720/4885 |
| US-20090042726-A1 | Novel Herbicides | DDT, CBR3, CBR1 | LMNA 4444/4885SMN1; SMN2 4014/4885NPC1 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.